SUBSCRIBE
SUBSCRIBE
News   Drug Development

GlaxoSmithKline (JOBS) Warns of Anemia Risk with Transplant Drug

September 4, 2009 | 
1 min read
Bookmark and Share

Reuters -- GlaxoSmithKline PLC and U.S. regulators said on Thursday they had notified healthcare professionals that a type of anemia has been reported in some patients treated with transplant drug Myfortic.
Clinical research Postmarket research
GSK
MORE ON THIS TOPIC
Insights
France’s biotech ecosystem: science, capital and scale
May 28, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Find Business Growth Opportunity, Business Standing Analyzing Arrow Gate
Rare diseases
FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug
May 27, 2026
 · 
3 min read
 · 
Heather McKenzie
Customer feedback giving rating based on experience or quality from product and service, survey, opinion and review to evaluate result, man trying to push customer feedback bar to be excellent smile.
Immunology and inflammation
Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss
May 27, 2026
 · 
3 min read
 · 
Annalee Armstrong
Vaccines
Lilly just bought renowned regulator Peter Marks a pipeline to play with
May 27, 2026
 · 
2 min read
 · 
Annalee Armstrong